The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Peripheral Exendin-4 and Peptide YY3–36 Synergistically Reduce Food Intake through Different Mechanisms in Mice
Abstract
Glucagon-like peptide-17–36NH2 (GLP-1) and peptide YY3–36NH2 (PYY3–36NH2) are cosecreted from the intestine in response to nutrient ingestion. Peripheral administration of GLP-1 or PYY3–36NH2 decreases food intake (FI) in rodents and humans; however, the exact mechanisms by which these peptides regulate FI remain unclear. Male C57BL/6 mice were injected (ip) with exendin-41–39 (Ex4, a GLP-1 receptor agonist) and/or PYY3–36NH2 (0.03–3 μg), and FI was determined for up to 24 h. Ex4 and PYY3–36NH2 alone decreased FI by up to 83 and 26%, respectively (P < 0.05–0.001), whereas a combination of the two peptides (0.06 μg Ex4 plus 3 μg PYY3–36NH2) further reduced FI for up to 8 h in a synergistic manner (P < 0.05–0.001). Ex4 and/or PYY3–36NH2 delayed gastric emptying by a maximum of 19% (P < 0.01–0.001); however, there was no significant effect on locomotor activity nor was there induction of taste aversion. Capsaicin pretreatment prevented the inhibitory effect of Ex4 on FI (P < 0.05), but had no effect on the anorexigenic actions of PYY3–36NH2. Similarly, exendin-49–39 (a GLP-1 receptor antagonist) partially abolished Ex4-induced anorexia (P < 0.05), but did not affect the satiation produced by PYY3–36NH2. Conversely, BIIE0246 (a Y2 receptor antagonist) completely blocked the anorexigenic effects of PYY3–36NH2 (P < 0.001), but had no effect on Ex4-induced satiety. Thus, Ex4 and PYY3–36NH2 suppress FI via independent mechanisms involving a GLP-1 receptor-dependent, sensory afferent pathway (Ex4) and a Y2-receptor mediated pathway (PYY3–36NH2). These findings suggest that administration of low doses of Ex4 together with PYY3–36NH2 may increase the suppression of FI without inducing significant side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“Consistent with these diverse biological actions, long-term administration of GLP-1 to obese or overweight patients with type 2 diabetes lowers fasting blood sugar and HbA1c levels and significantly reduces body weight despite the improvement in glycemic control (12).”
Signals That Regulate Food Intake and Energy Homeostasis
Woods, S. C., Seeley, R. J., Porte, D., & Schwartz, M. W. (1998) · Science · doi:10.1126/science.280.5368.1378 · Cited by 1,169
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Human distribution and release of a putative new gut hormone, peptide YY
Adrian, T. E., Ferri, G.-L., Bacarese-Hamilton, A. J., Fuessl, H. S., Polak, J. M., & Bloom, S. R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90211-2 · Cited by 1,065
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
H1-Receptor Antagonists: Comparative Tolerability and Safety
Estelle, F., & Simons, R. (1994) · Drug Safety · doi:10.2165/00002018-199410050-00002 · Cited by 751
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Thorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Biological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500
Self-citationInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
Barrachina, M. D., Martínez, V., Wang, L., Wei, J. Y., & Taché, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10455 · Cited by 440
The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats
Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., Niijima, A., Furuya, M., Inomata, N., Osuye, K., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1266 · Cited by 431 · cited 4×
“Recently, mRNA transcripts for the GLP-1 and Y2-receptors have been localized in the rat nodose ganglion, which contains the cell bodies of afferent vagal neurons (35, 36).”
BackgroundInfluentialBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
Self-citationBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · cited 4×
“The GLP-1-related gut peptide, oxyntomodulin is known to require the GLP-1/GLP-1R signaling pathway to exert its anorexigenic effect (45, 46).”
BackgroundInfluentialSelf-citationChallis, B. G., Coll, A. P., Yeo, G. S. H., Pinnock, S. B., Dickson, S. L., Thresher, R. R., Dixon, J., Zahn, D., Rochford, J. J., White, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306931101 · Cited by 371
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats
Dakin, C. L., Small, C. J., Batterham, R. L., Neary, N. M., Cohen, M. A., Patterson, M., Ghatei, M. A., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2003-1338 · Cited by 342
Savage, A. P., Adrian, T. E., Carolan, G., Chatterjee, V. K., & Bloom, S. R. (1987) · Gut · doi:10.1136/gut.28.2.166 · Cited by 334
Kinzig, K. P., D'Alessio, D. A., & Seeley, R. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10470.2002 · Cited by 296
Nakagawa, A., Satake, H., Nakabayashi, H., Nishizawa, M., Furuya, K., Nakano, S., Kigoshi, T., Nakayama, K., & Uchida, K. (2004) · Autonomic Neuroscience · doi:10.1016/j.autneu.2003.11.001 · Cited by 295
Does gut hormone PYY3–36 decrease food intake in rodents?
Tschöp, M., Castañeda, T. R., Joost, H. G., Thöne-Reineke, C., Ortmann, S., Klaus, S., Hagan, M. M., Chandler, P. C., Oswald, K. D., Benoit, S. C., et al. (2004) · Nature · doi:10.1038/nature02665 · Cited by 292
A second look at the barriers of the medial basal hypothalamus
Peruzzo, B., Pastor, F. E., Blázquez, J. L., Schöbitz, K., Peláez, B., Amat, P., & Rodríguez, E. M. (2000) · Experimental Brain Research · doi:10.1007/s002219900289 · Cited by 273
Energy Homeostasis, Obesity and Eating Disorders: Recent Advances in Endocrinology
Gale, S. M., Castracane, V. D., & Mantzoros, C. S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.2.295 · Cited by 265
Larsen, P. J., Fledelius, C., Knudsen, L. B., & Tang-Christensen, M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2530 · Cited by 257
Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract
Ward, S. M., Bayguinov, J., Won, K., Grundy, D., & Berthoud, H. R. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10801 · Cited by 243
Peptide YY3–36Inhibits Food Intake in Mice through a Melanocortin-4 Receptor-Independent Mechanism
Halatchev, I. G., Ellacott, K. L. J., Fan, W., & Cone, R. D. (2004) · Endocrinology · doi:10.1210/en.2003-1754 · Cited by 237
Intravenous Infusion of Peptide YY(3–36) Potently Inhibits Food Intake in Rats
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · Endocrinology · doi:10.1210/en.2004-1138 · Cited by 231
Effects of PYY[3–36] in rodent models of diabetes and obesity
Pittner, R. A., Moore, C. X., Bhavsar, S. P., Gedulin, B. R., Smith, P. A., Jodka, C. M., Parkes, D. G., Paterniti, J. R., Srivastava, V. P., & Young, A. A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802696 · Cited by 219
Szallasi, A., Nilsson, S., Farkas-Szallasi, T., Blumberg, P. M., Hökfelt, T., & Lundberg, J. M. (1995) · Brain Research · doi:10.1016/0006-8993(95)01094-7 · Cited by 206
Capsaicin and nociception in the rat and mouse: Possible role of substance P
Gamse, R. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00510129 · Cited by 205
Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R., & Niijima, A. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e808 · Cited by 204
McMahon, L. R., & Wellman, P. J. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.1.r23 · Cited by 199
Characterization of Blood-Brain Barrier Permeability to PYY3-36 in the Mouse
Nonaka, N., Shioda, S., Niehoff, M. L., & Banks, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051821 · Cited by 194
Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut
Böttcher, G., Sjölund, K., Ekblad, E., Håkanson, R., Schwartz, T. W., & Sundler, F. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90034-x · Cited by 190
BIIE0246: A selective and high affinity neuropeptide Y Y2 receptor antagonist
Doods, H., Gaida, W., Wieland, H. A., Dollinger, H., Schnorrenberg, G., Esser, F., Engel, W., Eberlein, W., & Rudolf, K. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00650-0 · Cited by 189
Moran, T. H., Smedh, U., Kinzig, K. P., Scott, K. A., Knipp, S., & Ladenheim, E. E. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00535.2004 · Cited by 189
Cholecystokinin and leptin act synergistically to reduce body weight
Matson, C. A., Reid, D. F., Cannon, T. A., & Ritter, R. C. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.4.r882 · Cited by 186
Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain
Van Dijk, G., Thiele, T. E., Donahey, J. C., Campfield, L. A., Smith, F. J., Burn, P., Bernstein, I. L., Woods, S. C., & Seeley, R. J. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r1096 · Cited by 179
Dumoulin, V. (1998) · Endocrinology · doi:10.1210/en.139.9.3780 · Cited by 167
de Fonseca, F. R., Navarro, M. A., Álvarez, E., Roncero, I., Chowen, J. A., Maestre, O., de Heras, R. G., Muñoz, R. M., Eng, J., & Blázquez, E. (2000) · Metabolism · doi:10.1053/meta.2000.6251 · Cited by 158
Medeiros, M. D. S., & Turner, A. J. (1994) · Endocrinology · doi:10.1210/endo.134.5.7908871 · Cited by 156
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives
Meier, J. J., Gallwitz, B., Schmidt, W. E., & Nauck, M. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01434-6 · Cited by 146
Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system
Gustafson, E. L., Smith, K. E., Durkin, M. M., Walker, M. W., Gerald, C., Weinshank, R. L., & Branchek, T. A. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00017-x · Cited by 141
Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat
Anini, Y., Fu–Cheng, X., Cuber, J. C., Kervran, A., Chariot, J., & Roz, C. (1999) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240050913 · Cited by 132
Self-citationObesity therapy: altering the energy intake-and-expenditure balance sheet
Crowley, V., Yeo, G. S. H., & O’Rahilly, S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd770 · Cited by 128
Synergy between amylin and cholecystokinin for inhibition of food intake in mice
Bhavsar, S., Watkins, J., & Young, A. W. (1998) · Physiology & Behavior · doi:10.1016/s0031-9384(98)00110-3 · Cited by 121
Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice
Åhrén, B. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00423.2003 · Cited by 108
Lachey, J. L., D’Alessio, D. A., Rinaman, L., Elmquist, J. K., Drucker, D. J., & Seeley, R. J. (2004) · Endocrinology · doi:10.1210/en.2004-0419 · Cited by 98
Self-citationComparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00376.2004 · Cited by 96
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94 · cited 1×
“agonist (24), the truncated form of PYY remains biologically”
BackgroundInteractions between gastric emptying and satiety, with special reference to glucagon-like peptide-1
Hellström, P. M., & Näslund, E. B. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00618-7 · Cited by 78
Adams, S. H., Won, W. B., Schonhoff, S. E., Leiter, A. B., & Paterniti, J. R. (2004) · Endocrinology · doi:10.1210/en.2004-0518 · Cited by 73
Wettergren, A., Maina, P., Boesby, S., & Holst, J. J. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709025098 · Cited by 64
A Glucagon-Like Peptide-1 Receptor Agonist and an Antagonist Modify Macronutrient Selection by Rats
Peters, C. T., Choi, Y.-H., Brubaker, P. L., & Anderson, G. H. (2001) · Journal of Nutrition · doi:10.1093/jn/131.8.2164 · Cited by 59
Self-citationArantes, R. M. E., & Nogueira, A. M. M. F. (1997) · Cell and Tissue Research · doi:10.1007/s004410050908 · Cited by 54
The potential role of glucagon-like peptide 1 in diabetes.
Meier, J. J., & Nauck, M. A. (2004) · PubMed · Cited by 39
Wang, T., Edwards, G. L., & Baile, C. A. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-219-44320 · Cited by 22
Peptides and obesity: the PYY3–36 story
Park, A., & Bloom, S. R. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.02.006 · Cited by 11
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Self-citationGastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“…total truncal vagotomy or surgical transection of brainstem-hypothalamic pathway in rodents (Abbott et al., 2005), and also by capsaicin, which causes selective degeneration of small diam- eter unmyelinated sensory neurons, including the nodose ganglion and the vagus nerve (Talsania et al., 2005).”
BackgroundGut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Self-citation
Metadata
- Authors
- Talsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-09-01
- Volume
- 146
- Issue
- 9
- Pages
- 3748-3756
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1983901940
- Cited by
- 306
- References
- 67
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.